Prostate Cancer Survival Rates
Results from a pre-specified interim analysis of Prostate Cancer Survival Rates, placebo-controlled Phase III study, COU-AA- 301, demonstrate that patients treated with the investigational agent abiraterone acetate plus low-dose prednisone/prednisolone showed a significant improvement in overall prostate cancer survival rate compared to patients treated with prednisone/prednisolone plus placebo. This study included 1,195 patients with metastatic advanced prostate cancer previously treated with one or two chemotherapy regimens, at least one of which contained docetaxel.
Study results of prostate cancer survivors were shared during a late-breaking presentation at the Presidential Symposium at the 35th Annual European Society for Medical Oncology Congress last week.
Treatment with abiraterone acetate from the data of prostate cancer survival rates plus low-dose prednisone/prednisolone resulted in a 35 per cent reduction in the risk of death (HR=o.6s; 95 per cent CI: 0.54, 0.77; p<o.oooi) and a 36 per cent increase in median survival (14.8 months vs 10.9 months) compared with placebo.
Patients on abiraterone acetate and low-dose prednisone/ prednisolone also showed significant improvements in secondary study endpoints when compared to the prednisone/ prednisolone plus placebo group: time to PSA progression (TTPP) [median 10.2 months for abiraterone acetate vs 6.6 months for placebo, HR=o.58 (95 percent CI: 0.46, 0.73); p<o.oooi) and an increase in radiographic progression-free survival (rPFS) [median 5.6 months for abiraterone acetate vs 3.6 months for placebo, HR=o.67 (95 per cent CI: 0.58, 0.78); p<o.oooi|.
Total PSA response, defined as greater than or equal to a 50 per cent decrease from baseline, was achieved in 38 per cent of patients treated with abiraterone acetate of prostate cancer therapy vs 10 per cent in the prednisone/prednisolone plus placebo arm [p<o.oooi].
The most frequent adverse events of Prostate Cancer Survival Rates were fluid retention (30.5 per cent vs 22.3 per cent) and hypokalemia (17.1 per cent vs 8.4 per cent).